CardioVia is developing a minimally invasive device that provides controlled access to the pericardial space, allowing physicians to perform procedures on the outer surface of the heart without the risk of puncturing the heart muscle. This technology addresses the high complication rates associated with current methods, which can lead to serious conditions such as cardiac tamponade and pericardial bleeding.
Funding
$840K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for accessing the pericardial space carry significant risks, including heart puncture, cardiac tamponade, and pericardial bleeding, leading to increased patient morbidity and mortality. These procedures often lack sufficient monitoring and control, requiring significant physician agility and precision due to the heart's constant motion and the proximity of critical structures.
Solution
CardioVia has developed the ViaOne Epicardial Access System, a minimally invasive device designed to provide controlled and safe access to the pericardial space. The system utilizes a concealed, blunt-tip needle with a unique geometric structure that differentiates between pericardial tissue and heart muscle, reducing the risk of puncturing the heart. Integrated sensors continuously monitor the device's position, facilitating safe navigation and entry. Once inserted, the device creates a stable workspace for various cardiac procedures, including arrhythmia ablation, lead placement, and targeted drug delivery.
Target Audience
The primary target audience includes electrophysiologists, cardiologists, and surgeons performing epicardial procedures, as well as hospitals and cardiac centers seeking to improve the safety and efficacy of cardiac interventions.
Features
- Concealed, blunt-tip needle with a unique geometric structure for safe pericardial access
- Integrated sensors for real-time monitoring and procedural guidance
- Intuitive, user-friendly design for streamlined operation
- Secure workspace creation for therapeutic access
- Controlled retraction of fluids
- FDA Breakthrough Device designation
- FDA-cleared for use in treating cardiac arrhythmias